Registration has ended
Info
ISPE Emerging Leaders - ATMP Online Seminar Series - Vol VI.
Gene Editing
The ISPE Emerging Leaders invite you to join our online seminar series 2022. In multiple volumes, you will learn about ATMP related topics. We will cover the basics of cell and gene therapy and tissue engineering, new manufacturing processes and the implications of these novel products on engineering and regulatory aspects.
This event is a joint initiative of the ISPE Emerging Leaders groups of the D/A/CH and Belgium affiliate.
For more information on the upcoming sessions, subscribe to our newsletter by checking the box in the registration form or follow us on LinkedIn.
Program - Vol VI. - 13.06.2023
| Time | Presenter | Topic |
| 17:30 - 17:45 | ISPE Emerging Leaders | Welcome by the moderators and introduction to ISPE Emerging Leaders and the seminar series |
| 17:45 - 18:15 | André Cohnen (Bayer AG) | Gene Editing at Bayer Pharmaceuticals |
| 18:15 - 18:45 | Marc Terrones (Center of Medical Genetics) | Gene editing: perspectives from research in oncology |
| 18:45 - 19:30 | All | Open Q&A with possibility to network with other participants |
More information about the speakers:
André Cohnen
Head of Genomic Medicine, Bayer
André Cohnen is Head of Genomic Medicine at Bayer Pharmaceuticals. His group focusses on both therapeutic gene editing and therapeutic RNA approaches. He has been active in the field of gene editing since early 2015, working on various collaborations, where he applied his team’s protein engineering expertise to CRISPR. André holds a PhD in Immunology and Cell Biology from Heidelberg University and worked as a PostDoc at Heidelberg and Oxford University before joining Bayer.
Marc Terrones Bernat
PhD Student, Human Molecular Genetics Group, Center of Medical Genetics Antwerp
Marc Terrones, BSc. in Biology and MSc. in Translational Medicine both at the University of Barcelona. During my master’s thesis, I developed a NOTCH1-mutant chronic lymphocytic leukemia (CLL) cell line using CRISPR/Cas9 to study the molecular patterns of drug resistance triggered by this mutation. I am currently doing my PhD at the department of Medical Genetics at the Antwerp University Hospital (UZA). My work focuses on the establishment of mutant ROS1+ non-small cell lung cancer (NSCLC) cell lines also using CRISPR/Cas9 as gene editing tool. The ultimate goal is to characterize the response of the different resistant mutant lines towards tyrosine kinase inhibitors using a multi-omics approach.
------